Patients With Non-Small-Cell Lung Cancer Respond Best to Salvage Chemotherapy When Pre-Treated With PD-1/PD-L1 Inhibitors
Patients with advanced non-small-cell lung cancer (NSCLC) who require salvage chemotherapy are 30% more likely to achieve a partial response if they have been pre-treated with a PD-1/PD-L1 checkpoint inhibitor compared to those who have not